Abstract Betaine therapy was given for 2 years to a 2-year-old boy with 5,
Introduction
Methylenetetrahydrofolate reductase (MTHFR) converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which donates a methyl group to homocysteine to form methionine. MTHFR deficiency results in elevated homocysteine and low methionine levels [6] . Betaine, a methyl donor, has been shown to successfully lower plasma homocysteine and normalize methionine in MHTR patients of varying age and disease severity [1] [2] [3] [4] 12] . In this paper, we report an infant successfully treated with betaine, with emphasis on the frequency of administration.
Case report
A 4-kg male, the third child of consanguineous parents, was delivered at 40 weeks of gestation after an uncomplicated pregnancy. Two siblings died 28 and 16 days; the latter having a positive urinary nitroprusside reaction. Subsequently, the mother received intramuscular cyanocobalamaine (1 mg every 2 weeks) and folic acid (5 mg/day) during pregnancy.
On day 2, the patient developed hyperbilirubinemia, hypotonia, and lethargy. Total plasma homocysteine (tHcy) was elevated (155. Carnitine%30, Santa Farma) were initiated. At 2 months, betaine anhydrous (100 mg/kg/day, given every 2 h; Cystadane®, Orphan Europe) was introduced.
No enzyme activity was detectable in fibroblasts (0 nmol methyl tetrahydrofolate/h/mg protein), confiming a severe MHTFR deficiency and betaine was increased weekly in 50 mg/kg increments to 3 g/day. Each dose, mixed with formula, was given nine times per day via nasogastic tube. From 9 months to 2 years, 6 g betaine/day was administrated orally with meals in six divided doses, mixed with food, milk, or juice. The effects of reducing the frequency to three per day and of increasing the dose to 9 g/day, given three or six times, on plasma tHcy and methionine were evaluated (Fig. 1) . Reducing the frequency to three per day increased tHcy from 45 μmol/L (5-15.5 μmol/L) to around 90 mmol/L and decreased methionine levels. Increasing to more than six per day led to difficulties in administration; 6 g/day of betaine given in six doses provided adequate control in this patient.
Physical development was normal; however, language development and motor development were retarded by 3 to 6 months. No vaso-occlusive or thromboembolic events occurred.
Discussion
The efficacy of betaine treatment in MTHFR deficiency is established. However, dosage and frequency of administration are still controversial. One study in patients with MTHFR deficiency showed peak betaine concentration after 1 and 2 h with an apparent elimination half-life of 1 h [7] . A comparison between 12 healthy males and three patients revealed an increased total plasma betaine clearance in patients, suggesting that, due to accelerated distribution and elimination kinetics, patients may require more frequent dosing to maintain plasma concentrations [8] . In this paper, mean tHcy levels of 45 µmol/L (5-15.5 µmol/L) were achieved by administration at short intervals. This is in contrast with data indicating minimal benefit from exceeding twice-daily dosing in six patients with classical homocystinuria [5] . In healthy individuals, betaine concentrations are not affected by age and gender. However, in patients with MTHFR deficiency and classical homocystinuria, this may not be the case. Patient age, primary diagnosis, metabolic status, and duration of treatment may explain such discrepancies. There is a need for further studies of betaine in MTHFR deficiency to optimize treatment modalities.
Additionally, one therapeutic action of betaine is to increase brain methionine uptake [11] . Increasing plasma methionine concentration via optimizing betaine therapy may enhance transportation into the brain [9, 10] .
In conclusion, more frequent administration of moderate doses of betaine in patients with MTHFR deficiency may provide clinical and biochemical benefits and should be evaluated further.
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